Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × Lead × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4 Brain Neoplasms 3 Neoplasms 2 Lung Neoplasms 2 Thrombophilia 1 Stomatitis 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Periodontitis 1 Neoplasms, Plasma Cell 1 Motor Activity 1 Liver Neoplasms 1 Liver Diseases 1 Head and Neck Neoplasms 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Febrile Neutropenia 1 EGFR-Mutant Lung Cancer 1 Deglutition Disorders 1 Communication Disorders 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Blood Coagulation Disorders 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 38 Fluorouracil 36 Capecitabine 28 pembrolizumab 26 Leucovorin 25 Docetaxel 24 Cisplatin 22 Paclitaxel 18 Carboplatin 16 Radiotherapy 15 Bevacizumab 15 Pemetrexed 14 130-nm albumin-bound paclitaxel 14 Irinotecan 13 Nivolumab 11 Albumin-Bound Paclitaxel 11 Ramucirumab 9 Cyclophosphamide 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 durvalumab 5 Taxes 5 Sorafenib 5 S 1 (combination) 5 Metformin 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01808638 2016-03-11

Atu027-I-02

Silence Therapeutics GmbH

Phase 1/2 Completed

Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡